Showing results (441-450 of 634) with videos related to
Sort By:
Pageof 64
Health Psychology Research|February 2, 2022
Role of Ketamine in the Treatment of Psychiatric DisordersSahar Derakhshanian, Maxine Zhou, Alexander Rath, et al.Journal of Pain and Symptom Management|August 22, 2020
Exploring Factors Associated With Long-Term Opioid Therapy in Cancer Survivors: An Integrative ReviewKatie Fitzgerald Jones, Mei R Fu, Jessica S Merlin, et al.Journal of Physics. Condensed Matter : an Institute of Physics Journal|May 24, 2019
Physical properties of epitaxial SrMnO2.5-δ F γ oxyfluoride filmsJiayi Wang, Yongjin Shin, Nicolas Gauquelin, et al.Diabetes, Obesity & Metabolism|May 17, 2018
Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trialRyuzo Kawamori, Masakazu Haneda, Keiko Suzaki, et al.Journal of Cardiac Failure|September 15, 2023
IV Diuresis in Alternative Treatment Settings for the Management of Heart Failure: Implications for Mortality, Hospitalizations and CostGinger Y Jiang, Christopher Lee, Stephen A Kearing, et al.Clinical Case Reports|July 31, 2019
A rare systemic etiology of heart failure and liver dysfunctionChristopher Lee, Edward Chau, Sumit Patel, et al.Journal of Agricultural and Food Chemistry|October 11, 2012
Ensilage and bioconversion of grape pomace into fuel ethanolYi Zheng, Christopher Lee, Chaowei Yu, et al.Oral and Maxillofacial Surgery|May 12, 2017
Where to position osteotomies in genioglossal advancement surgery based on locations of the mental foramen, canine, lateral incisor, central incisor, and genial tubercleJoshua S Park, Christopher Lee, Jason M Rogers, et al.Diabetes, Obesity & Metabolism|August 10, 2018
Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trialKohei Kaku, Masakazu Haneda, Yuko Tanaka, et al.Critical Reviews in Oncology/Hematology|March 2, 2010
Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastimPere Gascón, Matti Aapro, Heinz Ludwig, et al.Pageof 64